Abstract
The burden of multiple myeloma on patients’ HRQoL is significant and PROs should be considered for evaluating treatment patterns. This targeted review studies HRQoL in patients with TIE NDMM and RRMM receiving daratumumab combination regimens.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have